ArticleJournal of the National Cancer Institute2023

Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.

Jason V Evans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.